UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential
Credit Suisse initiated coverage on XOMA Corporation (NASDAQ: XOMA) with an Outperform rating and a $4 price target.
Credit Suisse commented, "Xoma has recently refocused its efforts and bolstered its balance sheet to advance the development of gevokizumab for multiple indications. Retained marketing rights, a well-designed clinical program, and multiple data readouts in the next 12 months provide for upside potential, although with speculative risk."
XOMA Corporation closed at $2.67 on Monday.
Latest Ratings for XOMA
|May 2015||Credit Suisse||Assumes||Neutral|
|Mar 2015||Ladenburg Thalmann||Upgrades||Neutral||Buy|
|Nov 2014||Ladenburg Thalmann||Downgrades||Buy||Neutral|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.